Clinical trials: Lung Metastases
COPD
Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves
Chronic obstructive pulmonary disease (COPD) affects 3.5 million people and is the third leading cause of death worldwide. Emphysema involves air retention in the lungs and is ultimately responsible for a major deterioration in…
- Trial name
- REPEAT (NCT06181357)
- Testing
- Endoscopic lung volume reduction in 2 stages, Endoscopic lung volume reduction in 1 stage
- Where
- 17 sites in France
- Volunteers
- 244 people
- Sponsor
- University Hospital, Limoges
Pulmonary Resection
Inflammatory Response Secondary Using Intravenous Anesthesia Versus Inhalation Anesthesia With Halogenated Agents
Lung ventilation required for lung resection surgery induces a proinflammatory response including cytokine production and recruitment of leukocytes and macrophages in the lung associated with postoperative complications, mainly…
- Trial name
- NCT02168751
- Testing
- propofol, Sevoflurane
- Where
- Spain
- Volunteers
- 180 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Thyroid Carcinoma, Metastatic Sites Lung Bone Nodal
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
- Trial name
- NCT00749697
- Testing
- SPECT scan
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease
Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria
This study will explore how people with sickle cell disease (SCD) develop a complication called pulmonary hypertension (PHTN), a serious disease in which blood pressure in the lungs is higher than normal.
- Conditions
- Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease, Pulmonary Hypertension
- Trial name
- NCT00367523
- Where
- Nigeria
- Volunteers
- 308 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lung Neoplasm, Brain Metastases
HA-WBRT-SIB for Brain Metastasis of Lung Cancer
Patients with lung cancer and brain metastases undergo HA-WBRT-SIB using image-guided radiotherapy, receiving a total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV is boosted to…
- Conditions
- Lung Neoplasm, Brain Metastases, Simultaneous Integrated Boost, Hippocampal Avoidance
- Trial name
- NCT06289023
- Testing
- HA-WBRT-SIB
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Adenocarcinoma, Colon Adenocarcinoma
Whole-Exome Sequencing (WES) of Cancer Patients
Cancers occur when the molecules that control normal cell growth (genes and proteins) are altered. Changes in the tumor genes and in the genes of normal cells are called "alterations." Many of these alterations can be detected by…
- Trial name
- NCT02127359
- Where
- 2 sites in United States
- Volunteers
- 244 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer Metastatic
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.
- Trial name
- GEODE (NCT03477474)
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Guardant Health, Inc.
Solid Tumor, Adult, NSCLC
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
- Conditions
- Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT05840510
- Testing
- Adagrasib, nab-Sirolimus
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Mirati Therapeutics Inc.
Metastatic Lung Cancer
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.
- Trial name
- LIBERTYLUNG (NCT04790682)
- Testing
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Carcinoma, Non-Small-Cell Lung
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns…
- Trial name
- FINN (NCT04794010)
- Where
- Germany
- Volunteers
- 825 people
- Sponsor
- Bristol-Myers Squibb
Immune Thrombocytopenia, ITP
Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP
Multicenter retrospective and prospective observational study based on the collection of sequential anonymized data from principal Italian ITP centers, to describe the clinical course of ITP patients becoming infected by…
- Conditions
- Immune Thrombocytopenia, ITP, Covid19, ITP Secondary to Infection
- Trial name
- NCT04735588
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Non-small Cell Lung Cancer, Metastasis From Other Cancers
Stereotactic Radiotherapy (SBRT) of Lung Metastasis
The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up.
- Trial name
- SBRT Lung (NCT01803542)
- Testing
- Stereotactic Radiation
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Non Small Cell Lung Cancer Stage IIIB
A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
This Phase 2 is a randomized study in advanced Non-Small Cell lung cancer patients to evaluate safety and efficacy of aerosolized BIO-11006 in conjunction with chemotherapy.
- Trial name
- NCT03472053
- Testing
- BIO-11006 plus standard of care, Standard of Care
- Where
- 11 sites in India
- Volunteers
- 60 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Metastatic Lung Cancer, Metastatic Gastrointestinal Cancer
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
This is an international, prospective study to assess the impact of concomitant early use of liquid biopsy (FoundationOne® Liquid CDx) within the diagnostic pathway, compared with the standard of care diagnostic pathway, on the…
- Trial name
- L1st (NCT05846594)
- Testing
- FoundationOne® Liquid CDx Assay, Standard of Care Diagnostic Pathway
- Where
- 18 sites in France, Germany and 2 more
- Volunteers
- 463 people
- Sponsor
- Hoffmann-La Roche
Brain Metastases from Non-small Cell Lung Cancer
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
This is a research study to find out if the new anti-cancer drug Durvalumab combined with radiation therapy to the brain will work in treating brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT04889066
- Testing
- Stereotactic Radiation Therapy, Durvalumab
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer, Metastasis to Liver
Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer
Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach.
- Conditions
- Breast Cancer, Metastasis to Liver, Metastasis to Lung
- Trial name
- NCT02581670
- Testing
- stereotactic radiation therapy (SRT)
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- Istituto Clinico Humanitas
Non-small Cell Lung Cancer (NSCLC)
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined with osimertinib in the study population and to…
- Trial name
- NCT03255083
- Testing
- DS-1205c, Osimertinib
- Where
- 7 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- Daiichi Sankyo
Brain Oligometastatic, Non-small Cell Lung Cancer
Brain Oligometastasis in NSCLC
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized.
- Trial name
- OligoLung (NCT07389642)
- Testing
- Standard treatments / multiple strategies
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Bordeaux
Small-cell Lung Cancer, Brain Metastases
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the…
- Conditions
- Small-cell Lung Cancer, Brain Metastases, SRS, Stereotactic Radiotherapy
- Trial name
- SHARP (NCT06457906)
- Testing
- Experimental group (SRS/SRT/Hypo-RT), Controled group (HA-WBRT)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences